MIT Student Receives the SBB Research Group Foundation STEM Scholarship
CHICAGO--(BUSINESS WIRE)--The SBB Research Group Foundation named Anantshri Asthana a recipient of its STEM scholarship. The $2,500 award empowers students to create value for society by pursuing higher learning through interdisciplinary combinations of Science, Technology, Engineering, and Mathematics (STEM).
Anantshri Asthana, a first-year undergraduate student, studies chemical engineering at Massachusetts Institute of Technology. He was one of four high schoolers to represent the U.S. at the International Chemistry Olympiad, showcasing their excellence in chemistry. He founded a nonprofit project that has provided free chemistry curriculum to over 6,000 people.
'Anantshri has such an outward-focused perspective on his work. I'm certain he'll make a huge contribution to his field," said Matt Aven, co-founder and board member of the SBB Research Group Foundation.
For eligibility criteria and more information on the Foundation's STEM scholarship, please visit http://www.sbbscholarship.org.
About the SBB Research Group Foundation
The SBB Research Group Foundation is a 501(c)(3) nonprofit that furthers the philanthropic mission of SBB Research Group LLC (SBBRG), a Chicago-based investment management firm led by Sam Barnett, Ph.D., and Matt Aven. The Foundation sponsors the SBB Research Group Foundation STEM Scholarship, supporting students pursuing Science, Technology, Engineering, and Mathematics (STEM) degrees. In addition to its scholarship program, the Foundation provides grants to support ambitious organizations solving unmet needs with thoughtful, long-term strategies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Cincinnati Reds pitching depth faces another possible hit with looming Wade Miley decision
CHICAGO – The Cincinnati Reds might lose another starting pitching option by the time they get home this week for a three-game series against division-rival Milwaukee Brewers. Veteran left-hander Wade Miley, who threw 87 pitches across five good innings in Triple-A Friday, has a June 1 opt-out on the minor-league deal he signed with the Reds in January. Wade Miley has been building up arm strength for the Reds at Triple-A Louisville, but the veteran can opt out of his minor league deal on June 1. 'We have to make a decision,' manager Terry Francona said. And manager Terry Francona suggested the likelihood of Miley exercising the clause if the Reds don't find a place for him on the big-league roster. Advertisement Reds trade Alexis Diaz Can Cincinnati Reds make Alexis Díaz trade windfall pay off at trade deadline? Reds Chicago Cubs Andrew Abbott Cincinnati Reds' Andrew Abbott makes All-Star pitch in dominant win over Cubs 'We have to make a decision,' Francona said. Miley, 38, who is in the final stages of rehab from 2024 Tommy John surgery, isn't expected to stay in Triple-A in the organization if the Reds decide not to promote him. 'I don't think so,' Francona said. 'He'll have opportunities to pitch.' Several teams that consider themselves playoff contenders have significant needs for starting pitching, including the last two teams that employed Miley: the NL Central-leading Chicago Cubs and the defending division-champ Milwaukee Brewers. Advertisement Miley, a former All-Star with 310 career starts and a 4.07 ERA, also has a reputation as a widely respected and popular clubhouse influence. Miley's split deal called for a base salary of $2.5 million (prorated) for time on the big-league roster. The Reds, who already have lost Carson Spiers (shoulder) and Rhett Lowder (oblique) to injuries for most or all of this season, don't appear to have an opening in a rotation manned by Andrew Abbott (1.51 ERA), Hunter Greene (2.36), Nick Martinez (3.48), Nick Lodolo (3.39) and Brady Singer (4.60). Further complicating the process is the fact Miley has had some short starts during his buildup, including one that lasted just two-thirds of an inning May 25. Advertisement 'It kind of hurt us in the fact that – it's not like they're gonna give you extra time,' Francona said. 'We've got to make a decision.' This article originally appeared on Cincinnati Enquirer: Big decision on Wade Miley looms for Cincinnati Reds
Forbes
27 minutes ago
- Forbes
Chicago Cubs Pitching Staff Will Need Trade Deadline Help
There are plenty of reasons to be surprised the Chicago Cubs are doing as well as they are at this point in the season. As May comes to a close, they have a solid lead in their division and are among the top teams in the National League. That's despite playing through the hardest strength of schedule in the first month of the season and going without their top two starting pitchers in Justin Steele and Shota Imanaga. Steele went down with an elbow injury in April that will keep him off the mound until 2026, and Imanaga has been out with a hamstring strain since May 5 and likely won't return for at least a couple of weeks. Those two factors could easily have sunk the Cubs' playoff hopes early in the season, but instead, Chicago is poised to be a buyer at the trade deadline in July. And on that front, it's fairly easy to discern where on the roster the Cubs could use the most help. Their starting pitching depth – buffeted by offseason additions like Colin Rea and Matthew Boyd – has handled the absences of Steele and Imanaga nicely, but there might be signs that the once-sturdy rotation is beginning to wobble. Rea struggled for the second straight start against the Reds on Friday, and the Cubs opted to use an opener for Ben Brown on Saturday. The Cubs were already likely candidates to be aggressive on the pitching market at the trade deadline, but if their remaining starting pitchers are going to struggle, then that likelihood only increases. They could pursue a top of the rotation type starter, but the Cubs have also had a lot of success in finding 'project' pitchers who come to Chicago and succeed in ways they have not in the past. 'We've had some real success stories organizationally with what we've done with pitching this year,' manager Craig Counsell told reporters Friday. 'We've got a good pitching program here, and that's just incrementally trying to make guys a little bit better. You take shots at this, right? You take just a number of shots. 'The player deserves a lot of credit, and some you just keep looking for those opportunities. That's the bottom line, is that you never stop, never get satisfied, never stop looking for those opportunities. That's something the organization [does] well.' If the Cubs decide to go after a top-tier starter, Marlins pitcher Sandy Alcantara is expected to be available. Even though Alcantara has an 8.47 ERA through 11 starts this season, the consensus among MLB executives seems to be that his track record and skill set will outweigh the numbers Alcantara is putting up this season. 'The longer he is removed from the injury the better he will likely be,' an American League executive told Mark Feinsand. 'At the Deadline, he could demand a pretty price with up to two-and-a-half years of control remaining on his contract.' And from a National League executive, 'It's not very often a Cy Young caliber starting pitcher is available on the market. If he gets back to his old ways, he can have a major impact on who ends up the eventual World Series champion.' Injuries and some under performances have also impacted the Cubs in the bullpen. Ryan Pressly, acquired in a trade with the Astros over the winter, has essentially lost the closer role. That spot was briefly occupied by Porter Hodge before he hit the injured list, and for now, Daniel Palencia is holding that responsibility. And along with that, Julian Merryweather, once a stabilizing force in the Cubs bullpen, was designated for assignment earlier this week because of his struggles on the mound. As a group, the Cubs' bullpen had a 13th-ranked ERA (3.77) going into Saturday's games, and they will likely have to bolster that part of the roster as well. The Cubs could look to the scuffling Orioles for help on that front. They are expected to have a handful of pitchers available come July, and any one of Felix Bautista, Gregory Soto, or Seranthony Dominguez would be a big help to the Cubs bullpen. They have the minor league depth to send the kind of return that Baltimore would be looking for, and relievers are traditionally not extremely costly at the trade deadline. The current Chicago Cubs roster has all of the ingredients for a division winner, and they have weathered some of the early season tests impressively. But in order to make the most of a 2025 season that is showing potential for their first National League Central title since 2017 and first postseason appearance since the 2020 wild card series, the Cubs are going to have to address some of the emerging needs on the roster. With an offense that leads baseball in runs scored, it's easy to see that they need to pursue pitching this summer.
Business Wire
37 minutes ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
